“…In previous studies, a collection of 1020 well-characterized nucleic acid extractions [5,6] from ethylenediaminetetraacetic acid (EDTA) blood taken from patients with clinical suspicion of malaria and extracted using the EZ1 DNA Blood 200 μL Kit (Qiagen, Hilden, Germany) had been completely assessed by four different NAT approaches in addition to microscopy of Giemsa-stained thick and thin blood films: -genus-specific loop-mediated isothermal amplification (LAMP) using the Meridian illumigene/ alethia Malaria platform (Meridian Bioscience Inc., Cincinnati, OH, USA) [5] -species-specific polymerase chain reaction (PCR) using the "FTD Malaria differentiation" real-time multiplex PCR kit (Fast Track Diagnostics [FTD], Sliema, Malta) for all samples, of which only the ones positively screened by RealStar Malaria PCR Kit 1.0 (altona Diagnostics, Hamburg, Germany) had been published so far [6] -genus-specific screening PCR using the RealStar Malaria PCR Kit 1.0 with subsequent discrimination using the RealStar Malaria S&T PCR Kit 1.0 (altona Diagnostics) in case of positive screening results [6] -species-specific in-house real-time PCR for all samples (unpublished data) using a previously described in-house SybrGreen real-time PCR assay [7], slightly modified exactly as described [8].…”